Monopar Therapeutics
For the period ended Jun 22, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 22, 2026 · Filed Apr 30, 2026
Use the contents to explore the available documents and sections.
Contents
PAY VERSUS PERFORMANCE
| Summary Compensation Table (“SCT”) Total for Principal Executive Officer (“PEO”) (1) · Compensation Actually Paid (“CAP”) to PEO (2) · Average SCT Total for Non-PEO NEOs (3) · CAP for Non-PEO NEOs (4) · Value of Fixed $100 Investment Based on Total Shareholder Return (“TSR”) · Net Income (Loss) (in thousands) | ||||||
|---|---|---|---|---|---|---|
| 2025 | $10,637,821 | $17,379,663 | $2,323,094 | $4,870,270 | $3,838.92 | $(13,717) |
| 2024 | $1,144,480 | $2,356,913 | $437,478 | $1,440,152 | $185.65 | $(15,586) |
| 2023 | $1,778,667 | $(166,177) | $879,812 | $13,507 | $14.35 | $(8,402) |
| (1) | The dollar amounts reported represent the amount of total compensation reported for our Chief Executive Officer Chandler D. Robinson for each corresponding covered fiscal year in the “Total” column of the Summary Compensation Table. |
| (2) | The CAP to our PEO in the table below reflects the adjustments required by applicable SEC rules from total compensation reported in the SCT. |
| (3) | The dollar amounts reported represent the average of the amounts of total compensation reported for our NEOs as a group (excluding our PEO) for each covered fiscal year in the “Total” column of the SCT. The NEOs (excluding our PEO) for fiscal year 2025 is Quan Vu from March 3, 2025, through December 31, 2025. The NEOs (excluding our PEO) for fiscal year 2024 are Karthik Radhakrishnan from July 1, 2024, through December 31, 2024, and Andrew Cittadine. The NEOs (excluding our PEO) for fiscal year 2023 are Kim R. Tsuchimoto and Andrew Cittadine. |
| (4) | The CAP to our NEOs on average in the table below reflects the adjustments required by applicable SEC rules from total compensation reported in the SCT. |
| 2025 | 2024 | 2023 | ||||
|---|---|---|---|---|---|---|
| PEO | Average Non-PEO NEOs | PEO | Average Non-PEO NEOs | PEO | Average Non-PEO NEOs | |
| Total compensation in SCT | 10,637,821 | 2,323,094 | 1,144,480 | 437,478 | 1,778,667 | 879,812 |
| Subtract grant date fair value of awards granted during covered year and shown in SCT | (8,967,821) | (1,754,226) | - | (43,070) | (1,068,167) | (494,461) |
| Add the fair value as of the end of the covered year of all awards granted during the covered fiscal year that were outstanding and unvested as of the end of the covered fiscal year | 11,409,695 | 2,350,590 | - | 229,272 | 86,418 | 40,003 |
| Add the amount equal to the change as of the end of the covered year (from the end of the prior year) in fair value (whether positive or negative) of any awards granted in any prior fiscal year that were outstanding and unvested as of the end of the covered year | 798,444 | 168,908 | 1,036,489 | 248,198 | (400,876) | (191,639) |
| Add, for awards that are granted and vest in the same covered year, the fair value as of the vesting date | 2,326,874 | 429,511 | - | 33,486 | 57,268 | 26,510 |
| Add the amount equal to the change as of the vesting date (from the end of the prior year) in fair value (whether positive or negative) of any awards granted in any prior year for which all applicable vesting conditions were satisfied at the end of or during the covered year | 1,174,649 | 200,595 | 260,850 | 53,751 | (151,818) | (48,989) |
| Subtract, for any awards granted in any prior year that fail to meet the applicable vesting conditions during the covered year, the amount equal to the fair value at the end of the prior fiscal year | - | (121,789) | (84,907) | (20,300) | (467,669) | (197,729) |
| Total Adjustment | $6,741,843 | $1,273,588 | $1,212,433 | $501,337 | $(1,944,844) | $(866,305) |
CAP versus Company Total Shareholder Return
As shown in the chart above, the Company’s TSR in 2025 was $3,838.92 based on a $100 initial fixed investment and the PEO CAP was $17.4 million. The 2025 non-PEO CAP was $4.9 million. The Company’s TSR in 2024 was $185.65 based on a $100 initial fixed investment and the PEO CAP was $2.4 million. The 2024 non-PEO CAP was $1.4 million. The Company’s TSR in 2023 was $14.35 based on a $100 initial fixed investment and the PEO CAP was $(0.2) million. The 2023 non-PEO CAP was $0.01 million. The Company does not use TSR as a primary metric to determine compensation levels or incentive plan payout.
Compensation Actually Paid versus Company Net Income
As shown in the chart above, the Company’s net loss in 2025 was $13.7 million and the PEO CAP was $17.4 million. The 2025 non-PEO CAP was $4.9 million. The Company’s net loss in 2024 was $15.6 million and the PEO CAP was $2.4 million. The 2024 non-PEO CAP was $1.4 million. The Company’s net loss in 2023 was $8.4 million and the PEO CAP was $(0.2) million. The 2023 non-PEO CAP was $0.01 million. The Company does not use net income/loss as a primary metric to determine compensation levels or incentive plan payout.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.